Primary Central Nervous System Lymphoma: Long-Term Treatment Outcomes and Cost-Analysis from a Retrospective Study of High-Dose Methotrexate Based Chemoimmunotherapy and Reduced Dose Radiation Therapy Approach.
Blood–brain barrier
CNS lymphoma
Diffuse large B cell
High dose methotrexate
Lymphoma
Real-world
Reduced dose whole brain radiotherapy
Rituximab
Journal
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
ISSN: 0971-4502
Titre abrégé: Indian J Hematol Blood Transfus
Pays: India
ID NLM: 9425818
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
28
01
2021
accepted:
01
05
2021
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
ppublish
Résumé
Standard treatment of primary central nervous system lymphoma (PCNSL) in countries with limited resources remains conventional chemotherapy, with or without whole brain radiotherapy (WBRT). To evaluate the treatment outcomes, prognostic factors and costs in patients with PCNSL treated with high-dose Methotrexate, vincristine and procarbazine, plus Rituximab (MVP-R) followed by consolidation with reduced dose (
Identifiants
pubmed: 35496970
doi: 10.1007/s12288-021-01444-7
pii: 1444
pmc: PMC9001787
doi:
Types de publication
Journal Article
Langues
eng
Pagination
223-234Informations de copyright
© Indian Society of Hematology and Blood Transfusion 2021.
Déclaration de conflit d'intérêts
Conflicts of InterestProf Nair R has received research grants, advisory board fees as well as Speaker fee from Cipla, Freisenius Kabi, Johnson and Johnson, Mylan, Novartis, and Dr Reddy’s Laboratory. Dr. RADHAKRISHNAN V reports advisory fees (institutional) and non-financial Institutional support from PFIZER, Institutional grants and non-financial support from INTAS Pharmaceuticals, Institutional grants from NATCO Pharmaceuticals, Institutional grants from ROCHE, Institutional grants from BMS, Institutional grants and non-financial support from CIPLA Pharmaceuticals, Institutional grants from EMCURE, personal fees (institutional) from ASTRA ZENECA, non-financial institutional support from Dr. REDDY’s Laboratories, outside the submitted work. Other authors declare no relevant conflicts of interest with respect to the submitted work.
Références
J Clin Oncol. 2003 Jan 15;21(2):266-72
pubmed: 12525518
Lancet. 2009 Oct 31;374(9700):1512-20
pubmed: 19767089
Neurology. 2002 May 28;58(10):1513-20
pubmed: 12034789
Int J Hematol. 2010 Nov;92(4):617-23
pubmed: 20967518
J Clin Oncol. 2013 Nov 1;31(31):3971-9
pubmed: 24101038
J Clin Oncol. 2003 Jul 15;21(14):2726-31
pubmed: 12860951
J Clin Oncol. 2006 Dec 20;24(36):5711-5
pubmed: 17116938
J Clin Oncol. 2003 Jun 15;21(12):2407-14
pubmed: 12805341
Acta Haematol. 2021;144(4):389-402
pubmed: 33242855
Ann Oncol. 2005 Mar;16(3):445-9
pubmed: 15653703
J Glob Oncol. 2019 Feb;5:1-9
pubmed: 30811305
J Neurooncol. 2002 Jun;58(2):175-8
pubmed: 12164690
Int J Radiat Oncol Biol Phys. 1992;23(1):9-17
pubmed: 1572835
J Neurosurg. 1989 Feb;70(2):190-4
pubmed: 2913217
Neuro Oncol. 2000 Jan;2(1):40-4
pubmed: 11302253
Cancer Cell. 2017 Jun 12;31(6):833-843.e5
pubmed: 28552327
Indian J Med Paediatr Oncol. 2017 Oct-Dec;38(4):478-482
pubmed: 29333016
J Clin Oncol. 2007 Oct 20;25(30):4730-5
pubmed: 17947720
Neurology. 2017 Jan 3;88(1):101-102
pubmed: 27864520
J Cancer Res Ther. 2020 Jan-Mar;16(1):13-17
pubmed: 32362603
Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):419-25
pubmed: 11567816
J Neurosurg. 1994 Aug;81(2):188-95
pubmed: 8027800
Oncologist. 2011;16(3):336-41
pubmed: 21346023
J Clin Oncol. 1996 Feb;14(2):556-64
pubmed: 8636771
Curr Opin Neurol. 2011 Dec;24(6):633-40
pubmed: 21968551
J Neurooncol. 2007 Nov;85(2):207-11
pubmed: 17896079
Clin Cancer Res. 2014 Feb 15;20(4):1029-41
pubmed: 24190981
J Clin Oncol. 2003 Mar 15;21(6):1044-9
pubmed: 12637469
Hematol Oncol. 2020 Dec;38(5):640-647
pubmed: 32510610
Neurol India. 2009 Nov-Dec;57(6):756-63
pubmed: 20139505
Lancet Haematol. 2016 May;3(5):e217-27
pubmed: 27132696
Lancet Oncol. 2010 Nov;11(11):1036-47
pubmed: 20970380
Lancet Haematol. 2015 Jun;2(6):e251-9
pubmed: 26688235
Blood. 2004 Jan 1;103(1):275-82
pubmed: 14504078
J Clin Oncol. 2002 Dec 15;20(24):4643-8
pubmed: 12488408